Vitrolife
167.7 SEK +2.69%Be the first to follow this company
Vitrolife is a global provider of solutions in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics in enhancing their practice as well as the outcome of a patient’s fertility treatment. Vitrolife´s products and services are available globally, and the company is headquartered in Gothenburg, Sweden.
Revenue
3.51B
EBIT %
-102.19 %
P/E
-
Dividend yield-%
0.6 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
VITR
Daily low / high price
163.4 / 168
SEK
Market cap
22.71B SEK
Turnover
13.46M SEK
Volume
81K
Financial calendar
Interim report
17.07.2024
Interim report
24.10.2024
Annual report
30.01.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest | 28.7 % | 28.7 % |
Bure Equity | 15.9 % | 15.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: Vitrolife Q1 update - Entering 2024 with low growth
Vitrolife AB (publ): Interim report Q1, 2024: Strong growth in APAC and solid margins
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools